GSK to nearly double cancer drugs in trials, WSJ reports

GSK expects its cancer drug pipeline to nearly double in 2027

Oncology chief Hesham Abdullah said GSK has about 15 cancer assets in trials and could run 19 to 20 late-stage studies next year

GSK to nearly double cancer drugs in trials next year, WSJ reports

In July, GSK said it expected to have more than 20 late-stage studies by the end of 2026, with three of the seven drugs identified for faster development ‌being cancer medicines

GSK to nearly double cancer drugs in trials, WSJ reports

Oct 27 (Reuters) - GSK expects ​to ‌nearly double the number ‌of ​cancer ⁠medicines it ⁠is testing in clinical trials ​next ⁠year, ⁠the Wall ​Street ​Journal reported on ‌Tuesday, citing an ⁠interview with a scientist ⁠at the ‌British ⁠drugmaker. (Rep...

GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.